Skip to main content
Journal cover image

A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC)

Publication ,  Journal Article
Beltran, H; Danila, D; Montgomery, B; Szmulewitz, R; Vaishampayan, U; Armstrong, A; Stein, M; Hoimes, C; Pinski, J; Scher, H; Puca, L; Wong, W ...
Published in: Annals of Oncology
October 1, 2016

Duke Scholars

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

27

Start / End Page

vi565

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beltran, H., Danila, D., Montgomery, B., Szmulewitz, R., Vaishampayan, U., Armstrong, A., … Tagawa, S. T. (2016). A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC). Annals of Oncology, 27, vi565. https://doi.org/10.1093/annonc/mdw435.21
Beltran, H., D. Danila, B. Montgomery, R. Szmulewitz, U. Vaishampayan, A. Armstrong, M. Stein, et al. “A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).” Annals of Oncology 27 (October 1, 2016): vi565. https://doi.org/10.1093/annonc/mdw435.21.
Beltran H, Danila D, Montgomery B, Szmulewitz R, Vaishampayan U, Armstrong A, et al. A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC). Annals of Oncology. 2016 Oct 1;27:vi565.
Beltran, H., et al. “A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).” Annals of Oncology, vol. 27, Oct. 2016, p. vi565. Scopus, doi:10.1093/annonc/mdw435.21.
Beltran H, Danila D, Montgomery B, Szmulewitz R, Vaishampayan U, Armstrong A, Stein M, Hoimes C, Pinski J, Scher H, Puca L, Bareja R, Wong W, Rubin M, Mosquera JM, Sboner A, Oromendia C, Nanus D, Ballman K, Tagawa ST. A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC). Annals of Oncology. 2016 Oct 1;27:vi565.
Journal cover image

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

27

Start / End Page

vi565

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis